Frontlight ResearchEarly access
Not yet recruitingPhase 3
Tranexamic acid during foot fusion surgery for deformity or osteoarthritis and infection rates
Tests tranexamic acid during foot fusion surgery, looking at infections after one year.
Key facts
- Who runs it
- HUS-yhtymae
- Where
- Finland3 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A clinical trial investigating Tranexamic Acid use in hind and midfoot arthrodesis surgery
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 450 people, planned
- Started
- 1 Jun 2026
- Expected to end
- 31 May 2029
- Type of study
- Interventional
- Record updated
- 29 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are going to have surgery to fuse joints in the back or middle of the foot (hind- or midfoot arthrodesis). It tests whether tranexamic acid given during surgery changes infection rates after one year.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- A foot and ankle surgeon has decided the person can have a hind- or midfoot fusion surgery. Conditions include deformity and osteoarthritis.
Main reasons for not taking part
- A sudden recent injury (acute trauma)
- A known blood clotting disorder that makes blood clot too easily, inherited or acquired, or a history of seizures
- Bone or joint infection in the area in the past 12 months, or an active bacterial infection or ulcer of the leg or foot
- Diabetes with GHb-A1C > 64mmol/l
- Severe blood flow problems in the leg, with no pulses felt in the foot
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age ≥ 18 years
- A foot and ankle orthopedic surgeon has determined that the patient is suitable for a hind- or midfoot arthrodesis procedure
- Ability to understand trial information and answer outcome assessments in Finnish or in Swedish
Who cannot take part
- Documented hypercoagulable disorder (inherited or acquired)
- History of seizures
- History of local bone or joint infection in the past 12 months
- Active bacterial infection or ulcer of the lower limb
- Diabetes mellitus and glycohaemoglobin (GHb-A1C > 64mmol/l)
- Patients with severe circulatory disorder of the lower limb, absence of palpable pulses in the foot
- Acute trauma
- Patient unable to provide consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the effect of intraoperative tranexamic acid on postoperative infection rates after mid- and hindfoot arthrodesis at one year
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Tranexamic Acid in Hind and Midfoot Arthrodesis Surgery: A Multicentre, Randomized, Placebo-Controlled Trial (TRASH Trial)
- Plain-language title
- Tranexamic acid during foot fusion surgery for deformity or osteoarthritis and infection ratesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 29 May 2026